当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Progress with covalent small-molecule kinase inhibitors
Drug Discovery Today ( IF 7.4 ) Pub Date : 2018-01-11 , DOI: 10.1016/j.drudis.2018.01.035
Zheng Zhao , Philip E. Bourne

With reduced risk of toxicity and high selectivity, covalent small-molecule kinase inhibitors (CSKIs) have emerged rapidly. Through the lens of structural system pharmacology, here we review this rapid progress by considering design strategies and the challenges and opportunities offered by current CSKIs.



中文翻译:

共价小分子激酶抑制剂的研究进展

随着毒性降低和高选择性的风险,共价小分子激酶抑制剂(CSKIs)迅速出现。通过结构系统药理学的角度,在这里我们通过考虑设计策略以及当前CSKI提供的挑战和机遇来回顾这一快速进展。

更新日期:2018-01-11
down
wechat
bug